PDCD1LG2 and neoplasm: To further characterize tumor immunological reshape after oncolytic HSV, we also looked from the same dataset from pilot in vivo study described in Fig. 1, the expression of checkpoint inhibitors widely used into the clinic in combination with oncolytic viruses (i.e., CTLA4, PD1 and its ligands PDL1/PDL2) [36].